Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Authors
Keywords
Biologics, Biosimilars, Switching, Clinical trials, Real world data
Journal
Current Rheumatology Reports
Volume 19, Issue 6, Pages -
Publisher
Springer Nature
Online
2017-06-16
DOI
10.1007/s11926-017-0658-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PROSIT-BIO Cohort
- (2017) Gionata Fiorino et al. INFLAMMATORY BOWEL DISEASES
- Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo: Table 1
- (2016) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Difference between Enbrel and Benepali treatment groups in ‘hepatobiliary disorders’
- (2016) Morton Scheinberg et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0145 Pharmacokinetics and Safety of GP2015, A Proposed Etanercept Biosimilar, and Etanercept Originator Product in Healthy Male Subjects: A Randomised Two-Way Crossover Study
- (2016) M. Afonso et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study
- (2016) J.S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0381 Safety and Efficacy of Switching from Innovator To Biosimilar Infliximab in Patients Affected by Spondyloarthritis. A 6-Month Observational Study
- (2016) A. Batticciotto et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- The changing landscape of biosimilars in rheumatology
- (2016) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
- (2016) Yoon Jung Lee et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The design of clinical trials to support the switching and alternation of biosimilars
- (2016) Freddy Faccin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Sa1957 Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe
- (2016) Martin Kolar et al. GASTROENTEROLOGY
- Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
- (2016) Maurizio Benucci et al. IMMUNOLOGIC RESEARCH
- P449. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months
- (2016) Journal of Crohns & Colitis
- P617. Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn’s disease
- (2016) Journal of Crohns & Colitis
- Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
- (2016) Lisa J. T. Smits et al. Journal of Crohns & Colitis
- The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
- (2016) Paolo Dapavo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
- (2016) Yoshiya Tanaka et al. Modern Rheumatology
- Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
- (2016) Eduardo Mysler et al. RHEUMATOLOGY INTERNATIONAL
- FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results)
- (2015) J. Vencovský et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0174 Clinical Experience with Infliximab Biosimilar – Switch from Remicade:
- (2015) T. Sokka et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
- (2015) Elena Nikiphorou et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tu1081 Preliminary Assessment of Efficacy and Safety of Switching Between Originator and Biosimilar Infliximab in Paediatric Crohn Disease Patients
- (2015) Jaroslaw Kierkus GASTROENTEROLOGY
- Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
- (2015) J. Sieczkowska et al. Journal of Crohns & Colitis
- Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
- (2015) Yoon Suk Jung et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
- (2015) Tsutomu Takeuchi et al. Modern Rheumatology
- Biosimilars in rheumatology: current perspectives and lessons learnt
- (2015) Thomas Dörner et al. Nature Reviews Rheumatology
- Clinical trial development for biosimilars
- (2015) Rieke Alten et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
- (2015) Sang Hyoung Park et al. Expert Review of Gastroenterology & Hepatology
- Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
- (2014) Yun-Seong Kang et al. DIGESTIVE DISEASES AND SCIENCES
- Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
- (2013) Howard Lee AAPS Journal
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)
- (2012) SoJeong Yi et al. BIODRUGS
- The advent of biosimilar therapies in rheumatology—“O Brave New World”
- (2012) Morton A. Scheinberg et al. Nature Reviews Rheumatology
- On the interchangeability of biologic drug products
- (2012) Laszlo Endrenyi et al. STATISTICS IN MEDICINE
- Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose, Two-Sequence, Crossover Study in Healthy Korean Male Volunteers
- (2011) Namyi Gu et al. CLINICAL THERAPEUTICS
- A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis
- (2010) R. D. INMAN et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period
- (2008) Jürgen Braun et al. ARTHRITIS AND RHEUMATISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started